The oncogenic role of PRMT4 has been described MM, and PRMT4-silecing using selective inhibitors, such as EZM2302 [69] or TP064 [70], was proven to exert anti-tumor activity in preclinical models of MM. Here, CARM1 is linked to Miyoshi myopathy.